Spironolactone with blood pressure drugs in primary aldosteronism patients
Observes spironolactone dosing and long-term heart and brain outcomes in adults with lateralized primary aldosteronism.
Plain-language title generated from the registry record
Registry title: Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism
Key facts
- Where
- Chongqing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Source: NCT07137364, who can take part
Where in China
- Daping Hospital, Army Medical Center of PLAChongqing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Third Military Medical University
- Trial code
- NCT07137364
- Record updated
- 22 August 2025
- Original description
The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is:Read full original descriptionShow less
Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism
The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is:
1. What is the long-term effect of spironolactone treatment for lateralized PA? 2. What is the optimal dose of spironolactone treatment for the relief of renin inhibition in patients with lateralized PA? Participants will receive spironolactone treatment as part of their regular medical care for more than 12 months, and their clinical indicators, including blood pressure, biochemical remission, cardiovascular and renal damage, and the incidence of cardiovascular and cerebrovascular events, will be analyzed.
Inclusion: Male or female, aged 30~65 years; PA patients with positive screening tests and saline suppression tests, and with AVS to determine lateralization. These patients have hypertension defined as office blood pressure ≥ 140/90 mmHg, or 24-hour ambulatory blood pressure showing average ≥ 130/80 mmHg, daytime blood pressure ≥ 135/85 mmHg, or nighttime blood pressure ≥ 120/70 mmHg; Patients with unilateral aldosterone-producing adenoma who decline surgery, or patients with non-adenoma, unilateral PA confirmed by AVS and meeting the above PA-related hypertension criteria; Provision of written informed consent to participate in the study.
Exclusion: Other confirmed secondary hypertension: pheochromocytoma, Cushing's syndrome, thyroid disorders, parathyroid disorders, acromegaly, renovascular disease, aortic disorders, chronic alcoholism, or drug dependence, etc; Adrenal insufficiency; Heart failure with NYHA class II-IV or stroke; Acute infection, malignancy, severe arrhythmia, psychiatric disorders, or drug/alcohol abuse; Renal impairment or have history of renal disease: serum creatinine > 1.5 × upper limit of normal (ULN), dialysis, or nephrotic syndrome; Significant hepatic dysfunction or have history of liver disease: AST or ALT > 2 × ULN, cirrhosis, hepatic encephalopathy, esophageal varices or portosystemic shunt; Hyperkalemia; Pregnancy or lactation; Participation in another clinical trial within the past 3 months; Inability to complete follow-up; Refusal to provide informed consent.